» Articles » PMID: 21151636

Oxaliplatin-Related Ocular Toxicity

Overview
Journal Case Rep Oncol
Publisher Karger
Specialty Oncology
Date 2010 Dec 15
PMID 21151636
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

We report the case of a 52-year-old woman with advanced colorectal cancer who was treated with oxaliplatin on a FOLFOX schedule. After 3 cycles of chemotherapy, she started to complain of visual loss, altered color vision and neurological symptoms. Due to the suspicion of ocular and neurological toxicity, antineoplastic treatment was stopped. Her visual field showed a concentric bilateral scotoma and the electrooculogram test revealed severe impairment of the retinal pigment epithelium. Visual acuity, color vision and visual field recovered completely 8 months later, although electrooculogram remained abnormal. Ocular toxicity has been reported as an infrequent adverse event of oxaliplatin. Findings in this case indicate toxicity of this chemotherapeutic agent on the retinal pigment epithelium, which has not been reported before. This damage could be permanent, and it thus differs from previously described oxaliplatin-induced ocular toxicities, which are usually transient and reversible. With increasing use of oxaliplatin as first-line treatment in advanced colorectal cancer, we have to be aware of this possible toxicity.

Citing Articles

Therapeutic Application of Hook for Retinopathy Caused by Ultraviolet Radiation and Chemotherapy Using ARPE-19 Cells and Mouse Retina.

Cheng C, Wang S, Lu C, Nguyen T, Shen S, Lien C Plants (Basel). 2024; 13(5).

PMID: 38475464 PMC: 10935344. DOI: 10.3390/plants13050617.


Corneal Nerve Changes Observed by In Vivo Confocal Microscopy in Patients Receiving Oxaliplatin for Colorectal Cancer: The COCO Study.

Tyler E, McGhee C, Lawrence B, Braatvedt G, Mankowski J, Oakley J J Clin Med. 2022; 11(16).

PMID: 36013010 PMC: 9409896. DOI: 10.3390/jcm11164770.


Amaurosis Fugax: A Rare Oxaliplatin-Induced Ocular Toxicity - A Report of Three Cases.

Tunio M, Phillips K, Baker P Case Rep Oncol. 2022; 15(1):133-137.

PMID: 35350803 PMC: 8921885. DOI: 10.1159/000521842.


Oxaliplatin-Associated Amaurosis Fugax.

Kubo K, Kimura N, Watanabe R, Higashino M, Tsuda M, Kato M Case Rep Oncol. 2021; 14(2):832-837.

PMID: 34248547 PMC: 8255733. DOI: 10.1159/000516271.


Transient Vision Loss - A Rare Oxaliplatin-Induced Ophthalmologic Side Effect: A Report of Two Cases.

Ah-Thiane L, Raoul J, Hiret S, Senellart H, Dumont F, Raimbourg J Case Rep Oncol. 2021; 14(1):483-486.

PMID: 33976624 PMC: 8077355. DOI: 10.1159/000514656.


References
1.
Leonard G, Wright M, Quinn M, Fioravanti S, Harold N, Schuler B . Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005; 5:116. PMC: 1266024. DOI: 10.1186/1471-2407-5-116. View

2.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

3.
Grothey A . Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003; 30(4 Suppl 15):5-13. DOI: 10.1016/s0093-7754(03)00399-3. View

4.
Simpson D, Dunn C, Curran M, Goa K . Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs. 2003; 63(19):2127-56. DOI: 10.2165/00003495-200363190-00013. View

5.
Grothey A . Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005; 5 Suppl 1:S38-46. DOI: 10.3816/ccc.2005.s.006. View